Research Article
Network Pharmacology-Based Strategy for Predicting Therapy Targets of Traditional Chinese Medicine Xihuang Pill on Liver Cancer
Table 3
The drug ingredients corresponding to hub nodes.
| | Hub nodes | Code | CTM | Ingredients |
| | VEGFA | Swiss-Prot:P15692 | Niuhuang | MOL008847 | | VEGFA | Swiss-Prot:P15692 | Ruxiang | MOL001280 | | VEGFA | Swiss-Prot:P15692 | Ruxiang | MOL001264 | | VEGFA | Swiss-Prot:P15692 | Ruxiang | MOL001266 | | VEGFA | Swiss-Prot:P15692 | Ruxiang | MOL001265 | | VEGFA | Swiss-Prot:P15692 | Ruxiang | MOL001268 | | VEGFA | Swiss-Prot:P15692 | Ruxiang | MOL001277 | | VEGFA | Swiss-Prot:P15692 | Moyao | MOL001003 | | VEGFA | Swiss-Prot:P15692 | Moyao | MOL000997 | | VEGFA | Swiss-Prot:P15692 | Moyao | MOL001023 | | VEGFA | Swiss-Prot:P15692 | Moyao | MOL001005 | | VEGFA | Swiss-Prot:P15692 | Moyao | MOL000989 | | VEGFA | Swiss-Prot:P15692 | Moyao | MOL001124 | | EGFR | Swiss-Prot:P00533 | Niuhuang | MOL008847 | | EGFR | Swiss-Prot:P00533 | Ruxiang | MOL000858 | | EGFR | Swiss-Prot:P00533 | Ruxiang | MOL001281 | | EGFR | Swiss-Prot:P00533 | Moyao | MOL001003 | | EGFR | Swiss-Prot:P00533 | Moyao | MOL000989 | | EGFR | Swiss-Prot:P00533 | Moyao | MOL001039 | | ESR1 | Swiss-Prot:P03372 | Shexiang | tcm03_006384 | | ESR1 | Swiss-Prot:P03372 | Shexiang | tcm03_006339 | | ESR1 | Swiss-Prot:P03372 | Shexiang | tcm03_001854 | | ESR1 | Swiss-Prot:P03372 | Shexiang | tcm03_003968 | | ESR1 | Swiss-Prot:P03372 | Niuhuang | MOL008836 | | ESR1 | Swiss-Prot:P03372 | Ruxiang | MOL001276 | | ESR1 | Swiss-Prot:P03372 | Ruxiang | MOL001272 | | ESR1 | Swiss-Prot:P03372 | Ruxiang | MOL001275 | | ESR1 | Swiss-Prot:P03372 | Ruxiang | MOL001264 | | ESR1 | Swiss-Prot:P03372 | Ruxiang | MOL001266 | | ESR1 | Swiss-Prot:P03372 | Ruxiang | MOL001265 | | ESR1 | Swiss-Prot:P03372 | Ruxiang | MOL001268 | | ESR1 | Swiss-Prot:P03372 | Ruxiang | MOL001277 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001203 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001198 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001003 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL000997 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001032 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001036 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001048 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001023 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001037 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001019 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001005 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001008 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001041 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001196 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL000989 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001079 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001124 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001134 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001072 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL001080 | | ESR1 | Swiss-Prot:P03372 | Moyao | MOL000993 | | PLG | Swiss-Prot:P00747 | Shexiang | tcm03_002894 | | PLG | Swiss-Prot:P00747 | Shexiang | tcm03_002385 | | MAPK3 | Swiss-Prot:P27361 | Ruxiang | MOL001266 | | MAPK3 | Swiss-Prot:P27361 | Ruxiang | MOL001265 | | MAPK3 | Swiss-Prot:P27361 | Ruxiang | MOL001268 | | MAPK3 | Swiss-Prot:P27361 | Moyao | MOL000997 | | MAPK3 | Swiss-Prot:P27361 | Moyao | MOL001036 | | MAPK3 | Swiss-Prot:P27361 | Moyao | MOL001023 | | MAPK3 | Swiss-Prot:P27361 | Moyao | MOL001037 | | MAPK3 | Swiss-Prot:P27361 | Moyao | MOL001019 | | MAPK3 | Swiss-Prot:P27361 | Moyao | MOL001124 |
|
|
CTM, Chinese traditional medicine; VEGFA, vascular endothelial growth factor A; EGFR, epidermal growth factor receptor; ESR1, estrogen receptor 1; PLG, plasminogen; MAPK3, mitogen-activated protein kinase 3.
|
